4.5 Article

rs2476601 T allele (R620W) defines high-risk PTPN22 type I diabetes-associated haplotypes with preliminary evidence for an additional protective haplotype

期刊

GENES AND IMMUNITY
卷 10, 期 -, 页码 S21-S26

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/gene.2009.87

关键词

PTPN22; haplotypes; type I diabetes; T1DGC

资金

  1. NCRR NIH HHS [U54 RR020278-05, U54 RR020278] Funding Source: Medline
  2. NIDDK NIH HHS [U01 DK062418, R01 DK061722, U01 DK062418-06] Funding Source: Medline

向作者/读者索取更多资源

Protein tyrosine phosphatase non-receptor type 22 (PTPN22) is the third major locus affecting risk of type I diabetes (T1D), after HLA-DR/DQ and INS. The most associated single-nucleotide polymorphism (SNP), rs2476601, has a C-> T variant and results in an arginine (R) to tryptophan (W) amino acid change at position 620. To assess whether this, or other specific variants, are responsible for T1D risk, the Type I Diabetes Genetics Consortium analyzed 28 PTPN22 SNPs in 2295 affected sib-pair (ASP) families. Transmission Disequilibrium Test analyses of haplotypes revealed that all three haplotypes with a T allele at rs2476601 were overtransmitted to affected children, and two of these three haplotypes showed statistically significant overtransmission (P = 0.003 to P = 5.9E-12). Another haplotype had decreased transmission to affected children (P = 3.5E-05). All haplotypes containing the rs2476601 T allele were identical for all SNPs across PTPN22 and only varied at centromeric SNPs. When considering rs2476601 'C' founder chromosomes, a second haplotype (AGGGGC) centromeric of PTPN22 in the C1orf178 region was associated with protection from T1D (odds ratio = 0.81, P = 0.0005). This novel finding requires replication in independent populations. We conclude the major association of PTPN22 with T1D is likely due to the recognized non-synonymous SNP rs2476601 (R620W). Genes and Immunity (2009) 10, S21-S26; doi:10.1038/gene.2009.87

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据